Co-Medical Director / Founding Member
Dr. Ehab Abdallah is the Managing Partner and MD Psychiatrist at Legacy Recovery Center bringing a wealth of expertise to his role. He obtained his medical degree from Alexandria University in Egypt and completed his residency in psychiatry at West Virginia University. Dr. Abdallah is triple board-certified in General Psychiatry, Consultation-Liaison (Psychosomatic) Psychiatry, and Addiction Psychiatry and Medicine.
With a specialized focus on addiction medicine, Dr. Abdallah has extensive experience treating individuals facing complex medical and psychiatric conditions. His dedication to high-quality care and genuine commitment to his patients’ well-being make him an invaluable member of the team.
In addition, Dr. Abdallah is a Fellow of the American Psychiatric Association and serves as a clinical assistant professor of psychiatry at the University of Arizona, where he educates and mentors medical students and residents.
After a period of prolonged and intense methamphetamine and cannabis use, a person suddenly begins having colorful visual hallucinations with an out-of-body experience, feels as if bugs are crawling under their skin, and becomes convinced they are being watched by space creatures. This is an example of drug (or substance)-induced psychosis.
It’s a temporary but serious mental health condition where an individual experiences a loss of contact with reality (psychosis). It is directly triggered by the use, intoxication, or withdrawal from a substance. And it may lead, in some cases, to a full-blown psychotic (schizophrenic), or bipolar episode.
In this article, I discuss the challenges of diagnosing the condition, explore the primary causes and mechanisms of drug-induced psychosis, detail its key symptoms, and outline the critical steps for effective treatment and sustainable recovery.
The Challenge of Diagnosing Substance-Induced Psychosis
Drug-induced psychosis is known medically as Substance-Induced Psychosis (SIP). According to the DSM-5, the manual psychiatrists use to diagnose mental health conditions, SIP is a condition featured by delusions and/or hallucinations developed during or within a month of substance intoxication or withdrawal. If they persist beyond a month, then a diagnosis of psychosis is probable.
SIP is a complex phenomenon, even for medical professionals. There are differing views on the condition and how to diagnose it. There is little knowledge regarding how common SIP is. In Scandinavia, over the past twenty years, there was an incidence of between 9.3 and 14.1 per 100.000 person-years, which has increased more recently with cannabis-induced psychosis [1].
Substance-induced psychosis can emerge suddenly, often with intoxication from high doses or long-term use of certain substances. It is transient, with symptoms resolving after the substance is cleared from the body. Persistent symptoms can occur in some cases, possibly leading to a syndrome directly resembling a primary psychotic disorder or schizophrenia-spectrum disorder.
In the dominant view by clinicians and researchers, SIP itself is not schizophrenia, which is caused by a complex interplay of genetic, neurological, and environmental factors. Schizophrenia-spectrum disorder is a primary, chronic brain disorder that is not dependent on substance use for its cause or continuation, although may be worsened by substance abuse [2].
The wide range of new psychoactive substances that have emerged in the last two decades make SIP much more complicated to diagnose and treat.
From a medical perspective, the challenge is how to clearly identify a substance-induced psychosis from a primary psychotic illness or a psychotic illness with co-occurring substance use. This is a central issue when psychiatrists are choosing the best therapeutic strategy for patients.
Primary Neurological Mechanisms for Substances Involved in SIP
In simple terms, SIP is caused when substances disrupt the brain’s delicate chemical balance, particularly its dopamine, serotonin, and other neurotransmitter systems.
The neurobiological mechanisms underlying different SIPs may vary from one drug to another. The occurrence of SIP is thought to be related to several disease mechanisms summarized here [2]. (Note: An agonist “turns on” a receptor, while an antagonist “turns it off” by blocking it.):
- Higher levels of central dopamine, especially for hallucinogens or psychedelic substances, stimulants, and derivatives of the khat plant, in synthetic form known as “bath salts”
- Cannabinoid CB1-receptor agonist for cannabis-related substances
- 5HT2A-receptor agonist for hallucinogenic plants and the latest phenethylamines (amphetamines) and tryptamine derivatives such as DMT and psilocybin
- Antagonist activity at NMDA receptors in ketamine and MXE
- k-opioid receptor activation in Sage of the Diviners (Salvia divinorum) and Kratom (Mitragyna speciosa)
Categories of Drugs Involved with SIP
Following is a list of common substances and the nature of the psychotic experience associated with them:
Stimulants
Methamphetamine, Cocaine, Cathinones/”Bath Salts”: Directly increase dopamine, leading to severe paranoia, aggression, and tactile hallucinations (e.g., feeling bugs on the skin). Approximately 40% of users have psychotic episodes [3].
Hallucinogens
LSD, Psilocybin, PCP: Distort perception and can cause “bad trips” that escalate into prolonged psychotic states, especially with high doses or pre-existing vulnerability.
Cannabis
High-THC Marijuana, Synthetic Cannabinoids like “Spice” or “K2“: THC can induce anxiety, paranoia, and psychotic episodes, particularly in adolescents and heavy users. The rising potency is a key concern.
Depressants & Others
Alcohol/Sedatives: Withdrawal can cause psychosis. MDMA and prescription medications can also be triggers in some cases.
Risk of Psychosis or Schizophrenia-Spectrum Disorders
It’s important to note that the majority of those who use these substances do not develop psychosis.
There is a complex relationship between psychotic symptoms and the use and abuse of illicit drugs. It is extremely difficult to distinguish between an induced psychosis and a re-exacerbation of a previously diagnosed disorder. As well, research subjects affected by SIP were more likely to abuse more than one drug and also seemed to show long-term hallucination after drug interruption [2].
In other research, subjects who presented psychotic symptoms after substance abuse seemed to have a higher risk of the development of a primary psychotic illness. In fact, recent studies provide strong evidence that they are more likely to develop a bipolar disorder, schizophrenia-spectrum disorder, or other primary psychotic disorder [2].
In the acute phase, SIP and schizophrenia are hard to distinguish. The diagnostic concept of SIP is under much debate among researchers and clinicians. One report stated that substance use alone is not sufficient to cause psychosis, and that other risk factors besides substance use are at play. These are risk factors that are also known to be associated with schizophrenia spectrum disorders [1].
Risk factors that may contribute to a psychosis include:
- Pre-existing mental health conditions (e.g., bipolar disorder, schizophrenia)
- High dosage and frequency of use
- Trauma history
- Younger age at the onset of substance abuse plays a fundamental role in the risk of a more probable conversion to a severe condition.
- Infection
- Family vulnerability (genetics) to psychosis (significantly more common in those who developed SIP compared to the general population)
In contrast to the prevailing views on the challenges of diagnosing SIP, some researchers suggest that substance use should be viewed as only one of many risk factors for SIP [1].
The authors of one study assert that SIP shares many features with the schizophrenia spectrum disorders. They argue that SIP could just as well be considered a first-episode psychotic disorder in patients with substance use [1]. The debate continues on this complex topic.
Rates of Progress from SIP to Other Mental Health Conditions
One study suggests that up to 32.2% of substance-induced psychoses may convert to either schizophrenia or bipolar disorder [2].
Another study found that around 25% of those who are initially diagnosed with SIP over time are subsequently diagnosed with a schizophrenia spectrum disorder [1] [4].
Yet a third study reported 4.5% for transition to bipolar disorder, with it being twice as high among women (7.1%) than among men (3.5%) [4].
Transition rates to schizophrenia spectrum disorder were higher among younger men and individuals with psychotic disorders induced by cannabis (36.0%) or multiple substances (32.0%) and lower among individuals with alcohol-induced psychosis (13.2%) [4].
Young men, particularly those with cannabis-induced psychosis, are at high risk of transition to schizophrenia spectrum disorder, and patients with repeated emergency admissions are an exceptionally high-risk group that could be targeted by early intervention efforts [4].
Episodes of self-harm after substance-induced psychosis are strongly linked to an increased likelihood of developing schizophrenia or bipolar disorder [5].
Recognizing the Psychotic Break: Symptoms and Diagnosis
The symptoms of substance-induced psychosis mirror those of primary psychotic disorders, creating a terrifying and disorienting experience for the individual.
Positive vs. Negative Symptoms
Positive Symptoms (Adding something to reality):
- Hallucinations: Hearing, seeing, or feeling things that aren’t there. Most common are auditory hallucinations.
- Delusions: Fixed, false beliefs (e.g., paranoia, grandiosity, believing one is being controlled by an external force).
- Disorganized Thinking/Speech: Incoherent, rapid, or illogical speech patterns.
Negative Symptoms (Taking something away): (Less common but possible):
- Social withdrawal
- Fattened affect (lack of emotional expression)
- Apathy
Behavioral and Emotional Signs
- Agitation, anxiety, and unpredictable or violent behavior.
- Social isolation and severe neglect of personal hygiene.
- Incoherence or difficulty holding a conversation.
Diagnosis: A Challenging Process
Methamphetamine psychosis shares so many clinical features with paranoid schizophrenia it is difficult to tell the two conditions apart [3]. A psychiatrist or other qualified medical professional must do the diagnosis, involving the following process:
Ruling Out Other Causes: Other medical conditions must be ruled out via a thorough medical workup (e.g. blood tests, brain scans).
Timeline is Critical: The diagnosis hinges on evidence that the symptoms developed during or soon after substance use or withdrawal. This information is critical.
Differentiating from Primary Psychosis: This is challenging, especially among methamphetamine users [3]. Doctors consider the length of the episode, family history, whether symptoms are present during periods of sobriety, and the specific nature of the symptoms.
The Road to Recovery: Treatment Options and Prognosis
Recovery from drug-induced psychosis is a multi-step process. It requires immediate medical stabilization, ongoing psychological support, and a commitment to sobriety.
The First Step: Acute Management and Medical Detox
The immediate goal is to rapidly ensure the safety of the individual and others. Often this happens in a hospital emergency department or inpatient clinic.
Medical Detoxification: Safely conduct a managed withdrawal from the substance, under medical supervision.
Short-term Medication: Prescribe antipsychotics (e.g., olanzapine, risperidone) to rapidly reduce psychotic symptoms. Benzodiazepines may be used for agitation and anxiety.
Follow-On Long-Term Therapeutic Strategies
Accessing the necessary medical and therapeutic support to ensure remission is best done in a residential treatment center or community-based clinic. Psychotherapy is strongly recommended for long-term recovery.
Especially for methamphetamine dependence, psychosocial treatment has a strong evidence base. It is the recommended first-line treatment to reduce rates of psychosis in methamphetamine users [3].
Cognitive Behavioral Therapy (CBT): Identifies and changes negative thought patterns, beliefs, and behaviors that fuel psychosis. By challenging distortions, it improves emotional regulation and develops coping strategies.
Motivational Interviewing (MI): Is a collaborative conversation style that strengthens a person’s own motivation and commitment to change by resolving their ambivalence about substance use treatment and sobriety.
Matrix Model: Is an intensive, structured therapy for substance use disorder (especially for amphetamines), combining relapse prevention, family education, and social support to promote recovery.
Family Therapy and Psychoeducation: To create a stable recovery environment. It’s essential to educate and support the family system.
Medication management: Medical supervision of antipsychotic medications, or for benzodiazepines for methamphetamine users.
Relapse Prevention and Sobriety
The single most important factor for a full recovery is complete abstinence from the triggering substance(s). Second, is a relapse prevention plan, including identifying triggers, building a support network (e.g., 12-step programs like Narcotics Anonymous) or SMART Recovery, and managing co-occurring mental health issues.
Integrated Treatment
Especially in the case of co-occurring methamphetamine use disorder and schizophrenia, there is a need for integrated treatment of both disorders, which should include:
- Intensive case management
- Vocational rehabilitation
- Housing
- Individual psychotherapy
- Relapse prevention
- Psychiatric services
Recovery Is Possible With the Right Supports
Many people make a full recovery. following prompt treatment and sustained sobriety. Nonetheless, the experience can be a “red flag” that indicates an underlying vulnerability to mental illness. For some individuals, an episode of SIP may reveal a chronic primary psychotic disorder such as bipolar or schizophrenia-spectrum disorder.
The key factor is to maintain ongoing management of the recovery journey. And it’s a sign of strength to seek help. Recovery is possible as is regaining one’s mental health with the right support, a commitment to sobriety, and professional guidance.
It’s essential to seek immediate help from a doctor, mental health professional, or a crisis hotline if you or a loved one has experienced SIP.
Get Expert Help at Legacy Recovery Center
Legacy Recovery Center is a highly rated, premier addiction and mental health treatment center in Arizona. Legacy is owned and operated by two psychiatrists with over 40 years of combined experience, as well as a robust therapeutic team.
We’re unique among residential treatment centers thanks to our ability to help people suffering from mental health and/or substance abuse issues. Our expert psychiatric team is equipped to treat multiple issues concurrently, focusing on your specific needs. Contact us today to being your journey!
Sources
[1] Bramness J. et al. 2024. Discussing the concept of substance-induced psychosis (SIP). Psychol Med. 2024. Aug;54(11):2852-2856.
[2] Fiorentini, A. (2021). Substance-Induced Psychoses: An Updated Literature Review. Frontiers in psychiatry, 12, 694863.
[3] Glasner-Edwards, S., & Mooney, L. J. (2014). Methamphetamine psychosis: epidemiology and management. CNS drugs, 28(12), 1115–1126.
[4] Vassos E. 2023. What is the Link Between Substance-Induced Psychosis and Primary Psychotic Disorders? American Journal of Psychiatry. Volume 180, Number 6.
[5] Baldaçara L et al 2023. Managing drug-induced psychosis. Int Rev Psychiatry. 2023 Aug-Sep;35(5-6):496-502.
